Rocket Pharmaceuticals highlights FDA-aligned RP-A501 Phase 2 results

Rocket Pharmaceuticals said it highlighted key findings and development milestones for RP-A501 from its FDA-aligned pivotal Phase 2 program during an Oct. 6 Danon disease investor webinar.